VIR BIOTECHNOLOGY INC (VIR)
US92764N1028 - Common Stock
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
VIR Makes Bullish Cross Above Critical Moving Average
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients
All 16 patients saw PSA declines of at least 50%. More than half reached a 90% decline in prostate-specific antigen levels.
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on stock movements.
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Monday's after hours session: top gainers and losers
Let's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Noteworthy Friday Option Activity: GSAT, VIR, INTC
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
Vir Biotechnology Becomes Oversold (VIR)
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024
VIR stock results show that Vir Biotechnology missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vir Biotechnology (NASDAQ:VIR) just reported results for the second quarter of ...
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier.
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise.
